Genocea Biosciences Inc (GNCA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Genocea Biosciences Inc (GNCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8007
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genocea Biosciences Inc (Genocea), formerly GenoceaInc, is a cancer vaccines provider. The company discovers and develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. It provides Gen-009 and Gen-010 neoantigen cancer Vaccine pipeline.Genoceaatlas technology uses a cellular assay to comprehensively re-create a patient’s actual immune response to cancer. The company’s Gen-009 cancer vaccines are being designed to educate T cells to recognize and attack specific targets and thereby kill cancers. It offers pre-clinical and clinical investigational immunotherapies. The compnay’s partnership program includes antigen discovery, immune responsw profiling, Gen-003 for general herpes and other disease programs.Genocea is headquartered in Cambridge, Massachusetts, the US.

Genocea Biosciences Inc (GNCA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genocea Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Genocea Biosciences Secures USD16.09 Million in Venture Funding from Auriga Partners 12
Genocea Biosciences Raises US$0.4 Million In Venture Financing 13
Genocea Biosciences Raises US$30 Million In Series C Financing 14
Partnerships 16
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 16
Genocea Biosciences Enters into Agreement with US Oncology Research 17
Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 18
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 19
Licensing Agreements 20
Genocea Biosciences Enters into Licensing Agreement with Oncovir 20
Equity Offering 21
Genocea Biosciences to Raise up to USD23.3 Million in Public Offering of Shares 21
Genocea Biosciences Raises USD53.4 Million in Public Offering of Shares 22
Genocea Biosciences Raises USD1.6 Million in Public Offering of Preferred Shares 24
Genocea Biosciences Raises USD50 Million in Public Offering of Shares 26
Genocea Biosciences Raises USD52 Million in Public Offering of Shares 28
Genocea Biosciences Raises USD2 Million in Private Placement of Shares 30
Genocea Biosciences Withdraws Public Offering of Shares 32
Genocea Biosciences Completes IPO For US$66 Million 33
Genocea Biosciences Inc – Key Competitors 35
Genocea Biosciences Inc – Key Employees 36
Genocea Biosciences Inc – Locations And Subsidiaries 37
Head Office 37
Recent Developments 38
Financial Announcements 38
Aug 02, 2018: Genocea reports second quarter 2018 financial and operating results 38
May 10, 2018: Genocea Reports First Quarter 2018 Financial and Operating Results 39
Feb 15, 2018: Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results 40
Nov 02, 2017: Genocea Reports Third Quarter 2017 Financial Results 42
Aug 09, 2017: Genocea Biosciences Reports Second Quarter 2017 Financial Results 44
May 04, 2017: Genocea Reports First Quarter 2017 Financial Results 45
May 04, 2017: Genocea Biosciences Q1 net loss increases 46
Feb 16, 2017: Genocea Reports Fourth Quarter and Year-End 2016 Financial Results 47
Corporate Communications 49
Mar 12, 2018: Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing 49
Feb 12, 2018: Genocea Biosciences Names Ali Behbahani, M.D., As Board Director 50
Mar 06, 2017: Howard Mayer, M.D., of Shire, Joins Genocea Biosciences’ Board of Directors 51
Product News 52
09/25/2017: Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccine GEN-009 52
04/18/2018: Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods 53
04/09/2018: Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines 54
Product Approvals 55
Apr 30, 2018: Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genocea Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genocea Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Genocea Biosciences Secures USD16.09 Million in Venture Funding from Auriga Partners 12
Genocea Biosciences Raises US$0.4 Million In Venture Financing 13
Genocea Biosciences Raises US$30 Million In Series C Financing 14
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 16
Genocea Biosciences Enters into Agreement with US Oncology Research 17
Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 18
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 19
Genocea Biosciences Enters into Licensing Agreement with Oncovir 20
Genocea Biosciences to Raise up to USD23.3 Million in Public Offering of Shares 21
Genocea Biosciences Raises USD53.4 Million in Public Offering of Shares 22
Genocea Biosciences Raises USD1.6 Million in Public Offering of Preferred Shares 24
Genocea Biosciences Raises USD50 Million in Public Offering of Shares 26
Genocea Biosciences Raises USD52 Million in Public Offering of Shares 28
Genocea Biosciences Raises USD2 Million in Private Placement of Shares 30
Genocea Biosciences Withdraws Public Offering of Shares 32
Genocea Biosciences Completes IPO For US$66 Million 33
Genocea Biosciences Inc, Key Competitors 35
Genocea Biosciences Inc, Key Employees 36

List of Figures
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Genocea Biosciences Inc (GNCA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Apotex Inc-製薬・医療分野:企業M&A・提携分析
    Summary Apotex Inc (Apotex) produces and markets a wide range of generic pharmaceuticals. It also undertakes the research, development, manufacture and distribution of non-prescription and private label medicines, fine chemicals and disposable plastics for medical use. The company has research and d …
  • Emera (Caribbean) Inc.:企業の戦略的SWOT分析
    Emera (Caribbean) Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Taylor Communications Inc:企業の戦略的SWOT分析
    Taylor Communications Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Orascom Development Egypt Sae
    Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report Summary Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • IHI Corporation (7013)-エネルギー分野:企業M&A・提携分析
    Summary IHI Corporation (IHI) is a heavy machinery engineering group. It provides technology oriented products and services to customers in the public, private and industrial sectors across the world. The group designs and manufactures a diverse range of products including ships and offshore facilit …
  • Catalyst Paper Corp:企業の戦略的SWOT分析
    Catalyst Paper Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Dynegy Inc:企業の発電所・SWOT分析2018
    Dynegy Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • Grasim Industries Ltd (GRASIM):企業の財務・戦略的SWOT分析
    Grasim Industries Ltd (GRASIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Nippon Telegraph and Telephone Corp (9432):企業の財務・戦略的SWOT分析
    Nippon Telegraph and Telephone Corp (9432) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Asahi Kasei Pharma Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescr …
  • Alion Science and Technology Corporation:戦略・SWOT・企業財務分析
    Alion Science and Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary Alion Science and Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • N V Nederlandse Gasunie:企業の戦略・SWOT・財務分析
    N V Nederlandse Gasunie - Strategy, SWOT and Corporate Finance Report Summary N V Nederlandse Gasunie - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Commonwealth Scientific and Industrial Research Organisation-製薬・医療分野:企業M&A・提携分析
    Summary Commonwealth Scientific and Industrial Research Organisation (CSIRO) is a national science agency that conducts research in climate adaptation, bio-security, renewable and energy, farming and food production, and information technology, and mining and manufacturing services, and others. The …
  • Ambry Genetics Corp-医療機器分野:企業M&A・提携分析
    Summary Ambry Genetics Corp (Ambry Genetics) is a biotechnology company that offers genetic testing services. The company offers clinical diagnostics services, which include tests, forms, billing, managed care, order kits, reporting, licenses, family studies program, variant classification and secur …
  • H.C. Starck GmbH:企業の戦略的SWOT分析
    H.C. Starck GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Reliance Infrastructure Ltd.:企業の戦略・SWOT・財務情報
    Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report Summary Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • San Leon Energy Plc (SLE):企業の財務・戦略的SWOT分析
    Summary San Leon Energy Plc (San Leon) is an oil and gas exploration and production company. It is engaged in acquiring, exploring and developing conventional and shale oil and gas assets across Europe and North Africa. The company holds interests in Durresi Block located in offshore Albania and inc …
  • Duke Realty Corporation:企業の戦略・SWOT・財務情報
    Duke Realty Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Realty Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Anadarko Petroleum Corp (APC):石油・ガス:M&Aディール及び事業提携情報
    Summary Anadarko Petroleum Corp (Anadarko) is an independent upstream oil and gas company, which carries out exploration, development, production, and marketing of natural gas, crude oil, condensate, and natural gas liquids (NGLs) from its assets. It also involves in gathering, processing, treating, …
  • Tech Mahindra Limited:企業の戦略・SWOT・財務情報
    Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report Summary Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆